IBD Unit, Gastroenterology, IRCCS Humanitas, Rozzano, Milan, Italy.
Curr Drug Targets. 2011 Sep;12(10):1417-23. doi: 10.2174/138945011796818216.
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized by chronic inflammation affecting the colonic mucosa, that can extend to the whole large bowel. The severity of mucosal lesions directly reflects the disease activity and severity and may be prognostic for an aggressive behavior of the pathology. Remission, is usually defined as resolution of symptoms. Recently, mucosal healing (MH) has emerged as an important end point of any short-term medical therapy for IBD. It may predict long-term remission and may impact on the natural history of the disease in Crohn's disease (CD), while data in UC patients are still limited. This review of the literature is focused on the recent evidence on the impact of medications on MH in UC and on the impact of MH on the natural course of UC.
溃疡性结肠炎(UC)是一种炎症性肠病(IBD),其特征为慢性炎症影响结肠黏膜,并可扩展至整个大肠。黏膜病变的严重程度直接反映了疾病的活动度和严重程度,并可能预示着病理学的侵袭性行为。缓解通常定义为症状的消除。最近,黏膜愈合(MH)已成为任何 IBD 短期药物治疗的重要终点。它可以预测长期缓解,并可能影响克罗恩病(CD)的疾病自然史,而 UC 患者的数据仍然有限。本文献综述重点关注药物对 UC 中 MH 的影响以及 MH 对 UC 自然病程的影响的最新证据。